$34.10
Today
as of Sep 4, 16:45 ET
Last 30 days
Recent Press Releases & News
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week
Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company?
Overview
52-week range
$10
$41
77% of range
Avg surprise (last 3)
-2.2%
Avg reaction (last 2)
-5.7%
0% positive
Latest IV / EM
57%
EM ±8.9% · $34 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.39 | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | $-0.37 | $-0.34 | -8.8% | +11.9% | -5.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.37 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.46 | $-0.44 | -4.5% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.42 | $-0.45 | +6.7% | — | -6.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.07 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.07 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.75 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.30 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.31 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $0.02 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 | $0 | — | $416,000 |
| Cost of revenue | — | — | — | $0 | $0 | $0 | — | $0 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-46M | $-44M | — | $-36M | $-43M | $-38M | — | $-76M |
| Net income | $-43M | $-41M | — | $-34M | $-41M | $-36M | — | $-73M |
| EPS (diluted) | $-0.39 | $-0.37 | — | $-0.37 | $-0.46 | $-0.42 | — | $-1.07 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $49M | $229M | $227M | $225M | $58M | $60M | $77M | $72M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $256M | $285M | $324M | $353M | $187M | $216M | $189M | $245M |
| Total assets | $265M | $294M | $333M | $363M | $195M | $220M | $194M | $251M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $25M | $20M | $27M | $31M | $27M | $18M | $29M | $55M |
| Total equity | $239M | $273M | $305M | $332M | $168M | $201M | $165M | $196M |